Regine Lehnert1, Mathias Pletz, Annicka Reuss, Tom Schaberg. 1. Federal Institute for Drugs and Medical Devices, Bonn; Center for Infectious Diseases and Infection Control, Jena University Hospital; Robert Koch Institute, Berlin; Agaplesion Diakoniekrankenhaus Rotenburg (Wümme).
Abstract
BACKGROUND: Amantadine, oseltamivir, and zanamivir are currently available in Germany for the prevention and treatment of influenza. We review their efficacy and side-effect profiles. METHODS: This review is based on pertinent randomized and controlled trials (RCTs) and systematic reviews retrieved by a systematic literature search, and on other relevant literature. RESULTS: The efficacy of antiviral drugs for the prevention of symptomatic influenza ranges from 60% to 90% (number needed to treat [NNT], 8-89) depending on the population and type of drug in question. Antiviral drugs shorten the duration of illness by 0.5-1.5 days when given within 48 hours of the onset of symptoms. Neuraminidase inhibitors do not significantly lower the incidence of bronchitis in adults, or of otitis media in children; they do have a positive effect against reported, but not necessarily diagnostically confirmed pneumonia in adults (NNT, 89 [50-232]). The RCTs yielded no information about possible effects on severe cases of influenza, or on mortality, as they included only mildly or moderately ill patients, but observational studies have yielded some evidence of benefit. The most common side effects of oseltamivir (>10%) are headache, nausea, and vomiting; of zanamivir (>1%), a skin rash; and of amantadine (>1%), loss of appetite, nausea, and central nervous effects. CONCLUSION: The benefits of antiviral drugs, particularly neuraminidase inhibitors, outweigh their risks. In deciding whether to use them, physicians should consider the properties of the currently circulating viruses and the patient's individual risk constellation, as directed in clinical treatment recommendations.
BACKGROUND:Amantadine, oseltamivir, and zanamivir are currently available in Germany for the prevention and treatment of influenza. We review their efficacy and side-effect profiles. METHODS: This review is based on pertinent randomized and controlled trials (RCTs) and systematic reviews retrieved by a systematic literature search, and on other relevant literature. RESULTS: The efficacy of antiviral drugs for the prevention of symptomatic influenza ranges from 60% to 90% (number needed to treat [NNT], 8-89) depending on the population and type of drug in question. Antiviral drugs shorten the duration of illness by 0.5-1.5 days when given within 48 hours of the onset of symptoms. Neuraminidase inhibitors do not significantly lower the incidence of bronchitis in adults, or of otitis media in children; they do have a positive effect against reported, but not necessarily diagnostically confirmed pneumonia in adults (NNT, 89 [50-232]). The RCTs yielded no information about possible effects on severe cases of influenza, or on mortality, as they included only mildly or moderately ill patients, but observational studies have yielded some evidence of benefit. The most common side effects of oseltamivir (>10%) are headache, nausea, and vomiting; of zanamivir (>1%), a skin rash; and of amantadine (>1%), loss of appetite, nausea, and central nervous effects. CONCLUSION: The benefits of antiviral drugs, particularly neuraminidase inhibitors, outweigh their risks. In deciding whether to use them, physicians should consider the properties of the currently circulating viruses and the patient's individual risk constellation, as directed in clinical treatment recommendations.
Authors: S Ewig; G Höffken; W V Kern; G Rohde; H Flick; R Krause; S Ott; T Bauer; K Dalhoff; S Gatermann; M Kolditz; S Krüger; J Lorenz; M Pletz; A de Roux; B Schaaf; T Schaberg; H Schütte; T Welte Journal: Pneumologie Date: 2016-02-29
Authors: Rachel J Jackson; Katy L Cooper; Paul Tappenden; Angie Rees; Emma L Simpson; Robert C Read; Karl G Nicholson Journal: J Infect Date: 2010-10-13 Impact factor: 6.072
Authors: J Burch; M Paulden; S Conti; C Stock; M Corbett; N J Welton; A E Ades; A Sutton; N Cooper; A J Elliot; K Nicholson; S Duffy; C McKenna; L Stewart; M Westwood; S Palmer Journal: Health Technol Assess Date: 2009-11 Impact factor: 4.014
Authors: Arnold S Monto; Michael E Pichichero; Steve J Blanckenberg; Olli Ruuskanen; Chris Cooper; Douglas M Fleming; Caron Kerr Journal: J Infect Dis Date: 2002-11-06 Impact factor: 5.226
Authors: Tom Jefferson; Mark A Jones; Peter Doshi; Chris B Del Mar; Carl J Heneghan; Rokuro Hama; Matthew J Thompson Journal: Cochrane Database Syst Rev Date: 2012-01-18
Authors: Stella G Muthuri; Sudhir Venkatesan; Puja R Myles; Jo Leonardi-Bee; Wei Shen Lim; Abdullah Al Mamun; Ashish P Anovadiya; Wildo N Araújo; Eduardo Azziz-Baumgartner; Clarisa Báez; Carlos Bantar; Mazen M Barhoush; Matteo Bassetti; Bojana Beovic; Roland Bingisser; Isabelle Bonmarin; Victor H Borja-Aburto; Bin Cao; Jordi Carratala; María R Cuezzo; Justin T Denholm; Samuel R Dominguez; Pericles A D Duarte; Gal Dubnov-Raz; Marcela Echavarria; Sergio Fanella; James Fraser; Zhancheng Gao; Patrick Gérardin; Maddalena Giannella; Sophie Gubbels; Jethro Herberg; Anjarath L Higuera Iglesias; Peter H Hoeger; Matthias Hoffmann; Xiaoyun Hu; Quazi T Islam; Mirela F Jiménez; Amr Kandeel; Gerben Keijzers; Hossein Khalili; Gulam Khandaker; Marian Knight; Gabriela Kusznierz; Ilija Kuzman; Arthur M C Kwan; Idriss Lahlou Amine; Eduard Langenegger; Kamran B Lankarani; Yee-Sin Leo; Rita Linko; Pei Liu; Faris Madanat; Toshie Manabe; Elga Mayo-Montero; Allison McGeer; Ziad A Memish; Gokhan Metan; Dragan Mikić; Kristin G I Mohn; Ahmadreza Moradi; Pagbajabyn Nymadawa; Bulent Ozbay; Mehpare Ozkan; Dhruv Parekh; Mical Paul; Wolfgang Poeppl; Fernando P Polack; Barbara A Rath; Alejandro H Rodríguez; Marilda M Siqueira; Joanna Skręt-Magierło; Ewa Talarek; Julian W Tang; Antoni Torres; Selda H Törün; Dat Tran; Timothy M Uyeki; Annelies van Zwol; Wendy Vaudry; Daiva Velyvyte; Tjasa Vidmar; Paul Zarogoulidis; Jonathan S Nguyen-Van-Tam Journal: Influenza Other Respir Viruses Date: 2016-02-01 Impact factor: 4.380